GlassScriptPhysician profile
Paola Chamorro
NPI 1821315557
$2,563.04
in general payments reported to CMS, 2019-2025
21 companies · $736 in 2025
The $736 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.53 · 2020: $130 · 2021: $325 · 2022: $400 · 2023: $277 · 2024: $671 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $498.46 | 2021-2025 | Tremfya |
| Abbvie INC. | $449.42 | 2020-2025 | Botox |
| Lilly USA, LLC | $271.37 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $252.50 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $192.44 | 2023-2025 | |
| Allergan, INC. | $169.05 | 2021-2022 | |
| Galderma Laboratories, L.P. | $129.25 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $124.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $95.44 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $58.79 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $57.47 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $51.06 | 2023-2025 | Bimzelx |
| Incyte Corporation | $43.27 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $29.10 | 2024 | Vtama |
| Biofrontera INC. | $28.54 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $27.33 | 2025 | Sofdra |
| Sun Pharmaceutical Industries INC. | $25.25 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.78 | 2025 | Sotyktu |
| Almirall LLC | $19.46 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.04 | 2023 | Siliq, Targretin |
| Mayne Pharma Commercial LLC | $6.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paola Chamorro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.